Serum ceramide levels are altered in multiple sclerosis.
Multiple sclerosis
ceramides
lipidomics
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
15
12
2020
medline:
19
11
2022
entrez:
14
12
2020
Statut:
ppublish
Résumé
Sphingolipids are myelin components and inflammatory signaling intermediates. Sphingolipid metabolism may be altered in people with multiple sclerosis (PwMS), but existing studies are limited by small sample sizes. To compare the levels of serum ceramides between PwMS and healthy controls (HCs) and to determine whether ceramide levels correlate with disability status, as well as optical coherence tomography (OCT)-derived rates of retinal layer atrophy. We performed targeted lipidomics analyses for 45 ceramides in PwMS ( Several ceramides, including hexosylceramides, lactosylceramides, and dihydroceramides, were altered in PwMS compared with HCs. Higher levels of Cer16:0 were associated with higher odds of EDSS worsening at 5 years in univariable (odds ratio (OR) = 3.84, 95% confidence interval (CI) = 1.41-10.43) and multivariable analyses accounting for age, sex, and race (OR = 2.97, 95% CI = 1.03-8.59). Each 1 ng/mL higher concentration of Hex-Cer22:0 and DH-HexCer22:0 was associated with accelerated rates (μm/year) of ganglion cell + inner plexiform layer (-0.138 ± 0.053, Ceramide levels are altered in PwMS and may be associated with retinal neurodegeneration and physical disability.
Sections du résumé
BACKGROUND
Sphingolipids are myelin components and inflammatory signaling intermediates. Sphingolipid metabolism may be altered in people with multiple sclerosis (PwMS), but existing studies are limited by small sample sizes.
OBJECTIVES
To compare the levels of serum ceramides between PwMS and healthy controls (HCs) and to determine whether ceramide levels correlate with disability status, as well as optical coherence tomography (OCT)-derived rates of retinal layer atrophy.
METHODS
We performed targeted lipidomics analyses for 45 ceramides in PwMS (
RESULTS
Several ceramides, including hexosylceramides, lactosylceramides, and dihydroceramides, were altered in PwMS compared with HCs. Higher levels of Cer16:0 were associated with higher odds of EDSS worsening at 5 years in univariable (odds ratio (OR) = 3.84, 95% confidence interval (CI) = 1.41-10.43) and multivariable analyses accounting for age, sex, and race (OR = 2.97, 95% CI = 1.03-8.59). Each 1 ng/mL higher concentration of Hex-Cer22:0 and DH-HexCer22:0 was associated with accelerated rates (μm/year) of ganglion cell + inner plexiform layer (-0.138 ± 0.053,
CONCLUSION
Ceramide levels are altered in PwMS and may be associated with retinal neurodegeneration and physical disability.
Identifiants
pubmed: 33307993
doi: 10.1177/1352458520971816
pmc: PMC8200368
mid: NIHMS1638871
doi:
Substances chimiques
Ceramides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1506-1519Subventions
Organisme : NIMH NIH HHS
ID : K01 MH121582
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS082347
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Mult Scler. 2020 May;26(6):624-639
pubmed: 32412377
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Cells. 2019 Sep 10;8(9):
pubmed: 31509962
Brain Behav Immun. 2015 May;46:280-92
pubmed: 25697397
Brain. 2019 Sep 1;142(9):2756-2774
pubmed: 31305892
EBioMedicine. 2019 May;43:392-410
pubmed: 30981648
Neurology. 2013 Jan 1;80(1):47-54
pubmed: 23267030
Sci Rep. 2018 Feb 15;8(1):3071
pubmed: 29449691
Cell. 2019 Dec 12;179(7):1483-1498.e22
pubmed: 31813625
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Ann Neurol. 2015 Nov;78(5):801-13
pubmed: 26190464
Nature. 2014 Jun 5;510(7503):58-67
pubmed: 24899305
Acta Neuropathol. 2012 Sep;124(3):397-410
pubmed: 22810490
Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
pubmed: 18216770
Neurotherapeutics. 2017 Oct;14(4):859-873
pubmed: 28812220
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Mult Scler. 2020 Apr;26(5):591-598
pubmed: 31965880
Nat Med. 2014 Oct;20(10):1147-56
pubmed: 25216636
Mult Scler. 2015 Sep;21(10):1271-9
pubmed: 25480867
Aging Cell. 2015 Feb;14(1):112-21
pubmed: 25345489
Immunol Cell Biol. 2015 Oct;93(9):825-36
pubmed: 25833068
Trends Mol Med. 2019 Jan;25(1):20-32
pubmed: 30477968
Clin Sci (Lond). 2018 Aug 17;132(17):1963-1976
pubmed: 30219773
Mult Scler. 2017 Dec;23(14):1938-1946
pubmed: 28155580
Ann Neurol. 2004 Feb;55(2):257-67
pubmed: 14755730
Brain. 2008 Nov;131(Pt 11):3092-102
pubmed: 18772223
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Brain. 2000 May;123 ( Pt 5):1027-40
pubmed: 10775547
Mult Scler. 2009 Sep;15(9):1011-29
pubmed: 19692432
Mult Scler. 2021 Apr;27(4):509-518
pubmed: 32669030
Mult Scler. 2019 Dec;25(14):1878-1887
pubmed: 30507269
Brain. 2014 Aug;137(Pt 8):2271-86
pubmed: 24893707